WO2014126510A2 - Polyvalent fusion protein vaccine against influenza - Google Patents

Polyvalent fusion protein vaccine against influenza Download PDF

Info

Publication number
WO2014126510A2
WO2014126510A2 PCT/RU2014/000096 RU2014000096W WO2014126510A2 WO 2014126510 A2 WO2014126510 A2 WO 2014126510A2 RU 2014000096 W RU2014000096 W RU 2014000096W WO 2014126510 A2 WO2014126510 A2 WO 2014126510A2
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
influenza
protein
vaccine
virus
Prior art date
Application number
PCT/RU2014/000096
Other languages
French (fr)
Other versions
WO2014126510A3 (en
Inventor
Ilya Vladimirovich DUKHOVLINOV
Anton Iosifovich ORLOV
Ljudmila Markovna TSYBALOVA
Oleg Ivanovich KISELEV
Original Assignee
Universal Biosystems Limited Company (Ubs Ltd)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universal Biosystems Limited Company (Ubs Ltd) filed Critical Universal Biosystems Limited Company (Ubs Ltd)
Priority to EP14751295.8A priority Critical patent/EP2956168B8/en
Priority to CN201480008848.7A priority patent/CN104994871B/en
Priority to EA201500770A priority patent/EA027463B1/en
Priority to MX2015010623A priority patent/MX362420B/en
Priority to UAA201508723A priority patent/UA115895C2/en
Priority to US14/768,107 priority patent/US9480737B2/en
Priority to CUP2015000083A priority patent/CU24288B1/en
Publication of WO2014126510A2 publication Critical patent/WO2014126510A2/en
Publication of WO2014126510A3 publication Critical patent/WO2014126510A3/en
Priority to HK16104349.2A priority patent/HK1216499A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the embodiment of present invention relates to molecular biology, biotechnology, preparative biochemistry, medicine, and can be used for prophylaxis of influenza, caused by existing influenza strains, as well as by possible reassortants.
  • fusion protein refers to a protein, obtained by an expression of a recombinant DNA molecule, in which coding arrays of several different genes are bound to one reading frame.
  • influenza virus affects from 5 to 15 percent of the population, causing acute respiratory diseases. Every year, vaccines against seasonal influenza are produced and widely used. However, a danger of pandemic spread of certain influenza virus strains with a new combination of genes exists. Such viruses can be more aggressive and cause a higher level of complications and fatalities. In 2009, an unfavorable situation took place, which was connected with an extension of the highly pathogenic influenza virus A(HlNl)pdm/09. Diseases were caused by the influenza virus with new antigenic determinants.
  • the new virus was a reassortant of viruses, circulating among both animals (swine) and humans.
  • WHO the infection ratio for humans, who had contact with contracted people, was 22% to 33% for A(H1N1) pdm/09.
  • the analog ratio for a seasonal influenza ranges from 5% to 15%.
  • the viral surface protein haemagglutinin (HA) is of particular interest in the light of development of the vaccines. HA is responsible for virus binding to cell receptors and in such a way for susceptibility to the disease. Mutations of HA usually lead to the increase of epidemiological and sometimes pandemic viral potential.
  • B-cell and T-cell response is being developed against antigenic determinants of viral proteins - the epitopes.
  • Usage of antigenic determinants of different viral subtypes in one construct makes the production of the polyvalent vaccine easier and allows to create effective vaccines against new viral strains.
  • fusion polypeptides which include a sequence with a high percentage of homology with the superficial HA-protein of the influenza A virus, containing five immunodominant antigenic epitopes (RU 92004487, 10.12.1992).
  • One of the suggested applications for such polypeptides is to provide vaccines against corresponding antigens, for treatment and prophylaxis (including immunotherapeutic methods) in case of infection by such antigens.
  • haemagglutinin of which subtypes is used.
  • the antigenic determinants of haemagglutinin of the influenza B virus as well should be taken into consideration, because the immunogenicity of the vaccine is limited by the strains, the sequences of which are used.
  • a polyvalent influenza vaccine which contains a polyvalent anti-influenza antigen, an adjuvant, an agent that provides the vaccine penetration, and an acceptable excipient (CN101450209, 31.12.2008). Antigens represented by HI -HI 6 and N1-N9 are declared as an antigenic component.
  • a polyvalent influenza vaccine is also known consisting of surface viral proteins A/H1N1, A/H3N2, haemagglutinin of the B-type (CN101524538,
  • an adjuvant - glycerol or aluminum hydroxide an adjuvant - glycerol or aluminum hydroxide.
  • the usage of both an acceptable adjuvant and antigenic determinants in the fusion construct, as well as using single protein type - haemagglutinin will allow to simplify and reduce the cost for the production of the vaccine, inasmuch as it will be no more necessary to adjust the conditions and to control the quality of the component production.
  • a polyvalent vaccine is known which is based on the inactivated viruses.
  • the active component is represented by antigens A/H1N1, H3N2, B, H5N1, and A (HlNl)pdm/09 (CN10173271 1, 31.12.2009).
  • the listed antigens are extracted from the inactivated viruses, which means that the scaled-up production of the vaccine can be limited by possible problems, connected with the usage of viruses, especially influenza viruses. For instance, it is necessary to create appropriate working conditions, to handle easily transmitted highly pathogenic virus strains.
  • the listed antigens are separate proteins - the advantages of usage of a fusion construct are listed above.
  • the prototype of the invention is a mixture of flagella, containing at least four protein epitopes of influenza virus, which interact with human cells, whereat each one is being expressed separately in the flagellin of Salmonella (WO0032228, 30.11.1998).
  • the listed epitopes refer to the group consisting of: (i) one haemagglutinin epitope, interacting with B cells, (ii) one epitope of haemagglutinin (HA) or of a nucleoprotein (NP), which can bind to MHC molecules for representation to receptors on the surface of the T helper cells and (iii) at least two nucleoprotein (NP) epitopes or a matrix protein (M) which are restricted by the MHC antigens that dominate by the Caucasians and bind to cytotoxic T lymphocytes (CTL).
  • CTL cytotoxic T lymphocytes
  • flagellin FliC of Salmonella typhimurium fulfills an adjuvant function. Due to its interaction with Toll-like receptor-5 (TLR-5), FliC stimulates maturation of macrophages and dendritic cells, which results in induction of the immune response (Mc Dermott P. F.. High-affinity interaction between Gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect. Immun. - 2000. - V. 68. - p.:5525- 5529; Means T. . et al. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. - 2003. - V.170. - p. :5165-5175).
  • flagellin is one of the most promising and well-studied new- generation adjuvants.
  • the results of studies show that recombinant proteins, inoculated together with flagellin, possess higher immunogenic and antigenic properties. The responses to them are registered in shorter times and induce a more intense cellular and humoral immune response (Balaram, 2008).
  • the disadvantage of such invention lies in the complexity of the immunizing mixture.
  • the usage of a fused protein, containing B and T cell epitopes of different influenza A and B virus subtypes, and flagellin will trigger an intense immune response and lower the production costs. Therewithal, it is practical to use only components of flagellin.
  • Two receptor-activating sites were detected in the terminal sites of flagellin (aa 79-1 17 and aa 08- 439) (Tonyia, 2001).
  • TLR-5 is expressed on the cells of the innate immunity, epithelial, and endothelial cells (Sebastiani G. et al.
  • the present invention embodies the vaccine based on highly purified fusion protein
  • SEQ ID NO: l which includes fragments of the proteins HI (281 - 461 aa), H3 (466 - 505 aa), H5 (510 - 549 aa) of the influenza A virus, as well as a fragment of influenza B viral haemagglutinin (554 - 593 aa), and flagellin components - FliCl (1-169 aa) and FHC2 (182- 276 aa) as adjuvants; the components are joined via flexible hinges.
  • the represented protein fragments are conservative regions of haemagglutinins HI, H3, H5, and B.
  • the appropriate nucleotide sequence (SEQ ID NO:2) was calculated by reference to the occurrence of the codons in the protein- coding genes of E. coli; at the same time, the codons were chosen by reference of the decrease of dG of the corresponding mRNA.
  • the main technical result of usage of the invention is that the valency of the influenza vaccine increases: after introduction of the vaccine claimed in the present invention an immunity is developed against different subtypes of both influenza A and B viruses - against the existing and even against those subtypes that can appear as a result of reassortment of any other influenza virus strains. After the vaccine introduction, antibodies against the epitopes of haemagglutinin from different influenza virus strains are being produced in the body. Thus, an ability to produce antibodies in response to influenza virus infection is being developed. Thereafter, immune response upon the infection with any influenza virus will be developed faster, which will result in avoidance of the infection or the disease will be milder. Such approach will allow to eliminate the present disease.
  • flagellin components as a non-toxic adjuvant will increase the immune response, developed to the vaccine.
  • the technical result is also in lowering the price and speeding up of the vaccine production due to a single component (the fusion protein) production instead of a set of vaccine mixture (the prototype) components.
  • fusion protein - of the present invention For production of the fusion protein - of the present invention, standard methods of molecular biology and microbiology can be used, which are familiar to a person having ordinary skill in the art. Such methods are described in scientific literature.
  • FIG. 1 Dynamics of mice survival rate after infection with 1 LD/50 of virus A/PR/8/34 (H1N1). The days post infection are displayed on the horizontal axis, and the vertical axis shows the survival rate of mice in percents.
  • FIG. 1 Dynamics of mice survival rate after infection with 1 LD/50 of virus A/California/07/09(H1N1). The days post infection are displayed on the horizontal axis, the survival rate of mice in percents - on the vertical axis.
  • Serum IgG against influenza B/Florida/04/06 virus Serum IgG against the fusion protein. Serum dilution (the reciprocal value) is displayed on the horizontal axis, and the optical density at 450 nm - on the vertical axis.
  • FIG. 4 Serum IgG against the fusion protein. Serum dilution (the reciprocal value) is displayed on the horizontal axis, and the optical density at 450 nm - on the vertical axis. The recombinant protein was entrapped at the concentration of 3 ⁇ g/ml.
  • the planned fusion polypeptide is a complex multidomain protein (6 domains: FliCl, FliC2, HI, H3, H5, B).
  • For modeling of the multidomain protein following procedures were performed: estimation of the domain boarders, construction of a model of the full protein for estimation of the domains orientation, construction of models for each domain (using examples of 3D structures and ab initio-based modeling), docking of the models using the model of the full protein.
  • the modeled fusion protein consists of 593 amino acid residues; its amino acid sequence is given - SEQ ID NO:l. Analysis of the amino acid sequence of this protein via ProtParam program (http://au.expasy.org/tools/protparam.html) has shown that the molecular weight of the fusion protein is 63.6 kDa, pi 6.2.
  • Example 2 Production of nucleotide sequence encoding the fusion protein.
  • the amino acid sequence of the fusion protein that included FliCl, FHC2, HI, H3, H5, B fragments was translated into the nucleotide sequence (1785 bp), which was then optimized for the expression in E. coli cells (SEQ ID NO:2).
  • the synthesis of the present nucleotide sequence was performed via elongation of the overlapping oligonucleotides according to the described methods (Majumder, 1992).
  • the oligonucleotides represented fragments of the fusion gene being 70 nucleotides long, containing overlapping regions of 20 nucleotides.
  • the main primer requirements were as follows: their length should not exceed 60 nucleotides, while the fusionization sites should not be shorter than 20 nucleotides.
  • the artificial gene was cloned into the pGEM-T vector via Kpnl and Sad restriction sites.
  • the produced gene was flanked by additional restriction sites: EcoRI at the 5' end and Xhol at the 3' end.
  • the artificial gene was recloned into the expression vector pET24a via EcoRI and Xhol restriction sites.
  • Example 3 Production of plasmid DNA encoding the fusion protein. According to the methods described in the example 2, a nucleotide sequence was obtained for the purpose of production of the influenza vaccine.
  • the resulting gene was cloned into the pET24a plasmid for the purpose of subsequent expression in E. coli cells. Therefore, ligation of the gene and the pET24a vector via appropriate buffer and ligase was performed. The reaction was being performed at +20 °C for 2 hours.
  • a nucleotide sequence of the gene was produced for the purpose of creation of the influenza vaccine, and then it was cloned into the pET24a vector.
  • the E. coli cells of the strain DHIOB/R (Gibko BRL, USA) possessing following genotype: F-mcrA A(mrr-hsdRMS-mcrBC) (p80dlacZAM 15 AlacX74 deoR recAl endAl araD139 A(ara, leu)769 galU galKX- rpsL nupG were transformed with the resulted plasmid via electroporation.
  • the cells were being incubated in SOC medium (2% bacto- tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04, 20 mM glucose) for 40 min at +37°C.
  • SOC medium 2% bacto- tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04, 20 mM glucose
  • the plasmid DNA was extracted from the grown clones via Wizard Minipreps DNA Purification System kit (Promega, USA).
  • the purified plasmid DNA was analyzed via restriction assay and sequencing. In course of research, the clones were sampled, which contained DNA fragments of required size in their plasmids. Next, such plasmids were extracted for the subsequent induction of the gene expression.
  • Example 5 Obtaining the E. coli strain producing the fusion protein.
  • the nucleotide sequence of the protein was obtained for the purpose of production of the influenza vaccine and then was cloned into the pET24a plasmid; the resulted plasmid was amplified in the E. coli cells of the strain DH10B/R and then extracted.
  • protease genes encodes a short version of RNase E, so that intracellular mRNA degradation is reduced and its fermentative stability is increased.
  • the Ion- and ompr-mutations in protease genes allow obtaining high yields of non-proteolyzed recombinant proteins.
  • the E. coli cells of the strain BL21 with the genotype F- ompT hsdSB (rB-mB-) gal dcm mel31 (DE3) were prepared as following. The cells were being incubated at +37 °C overnight in 5 ml L-broth, containing 1% tryptone, 1% yeast extract and 1% sodium chloride. The culture was diluted 50-100 fold in fresh L-broth and was being cultivated in a shaking incubator at +37 °C until the optical density of 0.2-0.3 at 590 nm was measured. After having reached 0.3 OD, the culture was diluted in the fresh L-broth until 0.1 OD and was being cultivated for 30 min.
  • the culture in the volume of 100 ml was transferred to a sterile centrifuge tube, and cell pelleting was being performed at +4 °C, 5000 g for 10 min. The supernatant was discarded, and the cells were resuspended in deionized water to the initial volume under subsequent centrifuging. The washing steps were repeated three times. After washing, the cell pellet was resuspended in a small volume of deionized water and the suspension was being centrifuged for 30 sec at 5000 rpm in a microcentrifuge. The transformation of the competent cells was performed via electroporation.
  • plasmid DNA was added to 12 ⁇ of competent cells, and the suspension was mixed.
  • the subsequent electroporation was performed via pulse generator GVI-1 (St. Russia State Polytechnical University, St. Russia) in sterile chambers at 10 kV/cm for 4 msec. After transformation, the cells were being incubated in SOC medium (2% bacto tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04, 20 mM glucose) for 40 min at +37 °C.
  • SOC medium 2% bacto tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04, 20 mM glucose
  • 10-100 ⁇ cell suspension was transferred to selective LB medium (Gibco BRL, USA) containing kanamycin (100 ⁇ g/ml) for selection of the clones with the plasmids (producer strains).
  • the plasmid obtained after transformation of the competent E. coli cells provided a high level of expression of the encoded recombinant protein.
  • Example 6 Production of the fusion protein for the creation of the influenza vaccine in E. coli cells via induction of protein synthesis by 0.2% lactose according to Studier method.
  • the nucleotide sequence of the fusion protein for the creation of the influenza vaccine was obtained and cloned in the pET24a plasmid; the obtained plasmid was amplified in E: coli cells of the strain DH10B/R, extracted, and E. coli cells of the strain BL21 were transformed thereby for the purpose of induction of the target gene expression.
  • PYP-5052 medium containing 1% peptone (Gibco, USA), 0.5% yeast extract (Gibco, USA), 50 mM Na 2 HP0 4 , 50 mM K 2 HP0 4 , 25 mM (NH 4 ) 2 S0 4 , 2 mM MgS0 4 , 0.5% glycerol, 0.05% glucose and 0.2% lactose.
  • a single producer strain colony was inoculated into PYP-5052 medium, containing kanamycin (100 ⁇ g/ml). The fermentation was being performed at +37 °C in a thermostatic shaker at 250 rpm for 20 hours until no significant change in the OD 600 per hour measured. An aliquot of the cells was taken for the purpose of expressional analysis of the gene encoding the vaccine protein. The expressional analysis was performed via polyacrylamide gel electrophoresis (PAGE). The rest of the biomass was pelleted in the centrifuge at 9000 g.
  • PAGE polyacrylamide gel electrophoresis
  • the protein was extracted from the E. coli cells via cell lysis.
  • the cells were resuspended in the lysis buffer, containing 20 mM tris-HCl pH 7.5, 5 mM EDTA, and 1 mM phenoxymethylsulfonylfluoride (PMSF), on 1 g cells per 5-7 ml buffer basis.
  • the cell suspension was exposed to ultrasound 7 times for 30 sec at a 30 sec interval (22 kHz).
  • the lysate was being centrifuged for 10 min at +4 °C, 5000 g.
  • the supernatant was discarded, and the pellet was resuspended in 1 M urea solution on 10 ml per 1 g cells basis by intensive mixing.
  • the centrifuge step was repeated.
  • the supernatant was discarded, and the pellet was resuspended in 2 M urea solution of the same volume.
  • the centrifuge step was repeated. The supernatant was discarded.
  • the obtained product contained approximately 98% of the fusion protein at concentration of 1 mg/ml.
  • MgCl 2 was added to the fusion protein solution to reach the concentration of 6 mM.
  • the fusion protein was purified via Immobilized-Metal Affinity Chromatography (IMAC) using Ni-NTA Sepharose. The capture by this sorbent is performed due to 6 histidine residues on the N-terminus of the obtained recombinant protein.
  • the protein solution filtering was performed via PVDF filter with a pore diameter of 0.22 ⁇ . To the so obtained filtrate the sorbing agent - Ni-NTA sepharose - was given, which was equilibrated with refolding buffer, making allowance of the fact that 1 ml of the sorbent can bind not more than 40 mg of protein. The capture was being performed for 2 hours.
  • the sorbent was pelleted via centrifugation and transferred to a gravity chromatography column, containing 2 ml of the sorbent.
  • the step gradient elution was performed with 20 - 300 mM imidazole by 50% of the previous concentration at each step, using eluting solution at a volume of 5-20 fold of the column volume.
  • the yield and purity of the protein was controlled via disc electrophoresis and Bradford protein assay.
  • Standard stock endotoxin solution with the defined potency of 4000 EU was prepared.
  • the produced solution was stable for at least two weeks, when preserved at +4 °C.
  • a two-fold serial dilution was prepared in sterile polystyrene tubes, using endotoxin-free water. The tubes were sealed with endotoxin-free parafilm.
  • a five-fold and - after the preparatory endotoxin content evaluation - a two-fold serial dilution of the sample were prepared.
  • the sample, water, 100 ⁇ of endotoxin, and, at last, 100 ⁇ of LAL-reactive were put on the bottom of each eppendorf tube.
  • the mixture was being incubated for 1 hour at 37°C in a water bath.
  • the results were estimated by means of presence or absence of a firm clot on the bottom of the inverted tube. The absence of factors that inhibit clot formation in the analyzed sample was shown.
  • the gel clot was formed at a 1/8 sample dilution, it means that, taking into consideration the method sensitivity of 0.03 EU/ml, the sample with the concentration of 50 ⁇ g/ml contained less than 100 EU.
  • the conformation of the recombinant fusion protein during its biosynthesis in E. coli was determined via polyacrylamide discontinuous electrophoresis of the disrupted by sonication E. coli cells, after the induction of the expression.
  • both pellet and supernatant, formed after sedimentation of the cell lysate were analyzed. Densitometric analysis demonstrated that 100% of the recombinant protein, synthesized in E. coli producer strain, was accumulated in the supernatant, i.e. in the soluble fraction.
  • the obtained expression level did not change in the producer strain for 6 passages, which indicates a stable expression of the analyzed gene.
  • Example 8 Production of the recombinant fusion protein via cultivation of E. coli cells with continuous nutrient supply (preferred nutrients: glucose and yeast extract).
  • a fed-batch culture of Escherichia coli strain was used for the purpose of production of the fusion protein.
  • This method is preferred, when it is necessary to avoid substrate limitation and its negative consequences. Thereby, a substrate or any other essential components are being supplied either continuously, or in response to sensor signals.
  • This method can be used in case of a potentially toxic substrate (recombinant proteins are toxic for the E. coli cells), as its concentration in the medium will be kept at a low level.
  • the speed of substrate uptake can be limited by the speed of its transport.
  • the E. coli strain was passaged on the angular EDTA-containing agar under sterile conditions and was being incubated in the thermostat for 5 days. To obtain the inoculate, the culture was washed from the agar, passaged to a liquid EDTA-containing medium with, and cultivated for 3-4 days. Next, 10 ml inoculate was passaged into 750-ml flasks, containing 200 ml of sterile liquid medium, and cultivated in a thermostatic shaker at 150-200 rpm, 28 °C - 30 °C for 10 days.
  • the liquid growth medium was used to obtain the seed material and for periodic cultivation.
  • the gel growth medium was produced both as a liquid and with 3% agar.
  • the optical density (OD 600 ) of the E. coli cell culture was 9.
  • the cells were sedimented via centrifugation at 13000 g for 6 min at 10 °C.
  • the cell pellet was weighted; its weight was 2.1 g.
  • the cells were resuspended in 30 ml buffer (50 mM TrisHCl, 50 mM EDTA, 20 mM L-cysteine, pH 8.6) and disrupted by ultrasound (sonication time - 10 min, impulse time - 30 sec, pause between the impulses - 30 sec, amplitude - 70%).
  • the inclusion bodies were pelleted under centrifugation at 30000 g for 20 min at 10 °C; the wet weight of the inclusion bodies was 1.45 g. the pelleted inclusion bodies were washed with several buffers according to the following scheme:
  • the inclusion bodies were pelleted via centrifugation at 30000 g for 20 min at
  • the wet weight of the inclusion bodies was 0.7 g.
  • 18 ml of solution (9 M urea, 2 mM EDTA, 50 mM TrisHCl, pH 8.6) was used.
  • the solubilized inclusion bodies were being centrifuged at 30000 g for 20 min at 10 °C.
  • the developed supernatant was transferred in to the new falcons and was used for the refolding.
  • the refolding step was performed as follows: the solubilized inclusion bodies were
  • the step gradient elution was performed with 20 - 300 mM imidazole (20, 40, 100, 150, 200 H 300 mM), whereas at each step the volume of the eluting solution was 10 fold of the column volume.
  • Example 9 Production of the fusion protein, being purified before dilution, and removal of soluble cell components including DNA, RNA, proteins, lipopolysaccharides via washing with buffer solution, containing a guanidine hydrochloride detergent.
  • protein was solubilized in 18 ml of solution (8 M GuHCl, 2 mM EDTA, 50 mM TrisHCl, pH 8.6), containing guanidinium chloride.
  • the solubilized inclusion bodies were pelleted under centrifugation at 30000 g for 20 min at 10°C. The obtained supernatant was transferred to new falcons and used for refolding.
  • Example 10 Determination of immunogenicity of the obtained protein.
  • Immunogenicity is a capability of an antigen to initiate production of effectors that neutralize antigenic foreignness by immune system. In order to induce immune response, an antigen should be immunogenic.
  • immunogenicity is a complex feature, which depends on the properties of the antigen itself, the way of its penetration, and the way of immunization.
  • mice were immunized abdominally with 20 ⁇ g of the fusion protein. The immunization was performed twice, spaced two weeks apart. The animals were divided into experimental and control groups with 5-6 mice in each group. Blood samples were taken from the tail vein from 5-6 mice out of each group two weeks after the second immunization. To obtain serum, blood was incubated for 30 minutes at 37 °C. After clot formation, the samples were transferred on ice, cooled down for 1 hour, and then centrifuged for 15 minutes at 400 g. Mice blood sera from each group were pooled and frozen at -20 °C. Antibody titers in the sera of the immunized mice were determined via enzyme-linked immunosorbent assay, (ELISA). ELISA was performed according to conventional technology. 96-well plates were used (Greiner, Germany), on which the fusion protein was sorbed (in carbonate buffer, pH 9.5-9.6) and incubated over night at 4 °C.
  • ELISA enzyme-linked immunosorbent assay
  • polyclonal rabbit anti-mouse radish peroxidase- conjugated IgG antibodies (Abeam, UK), diluted 1 :8000, were used. TMB was used as a substrate. Detection was performed at 450 nm. The endpoint titer was the highest dilution that gives an optical density of 2 standard deviations above negative control - serum of non- immunized mice at the same dilution.
  • the results show a high immunogenicity of the obtained protein. After immunization with the fusion protein, antibodies to the antigen were detected, titer is 51 200.
  • Example 11 Protective effect of the vaccine based on the fusion protein against different influenza virus strains.
  • mice In the present research 30 Balb/c female mice aged 7-8 weeks (16-18 g weight) were used, which were received from the branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS (IBCh RAS) - Animals Breeding Center "Pushchino".
  • the laboratory animals were healthy and helminths-free (veterinary certificate 250 N° 0187942 of November 27 2012).
  • the animals were kept in the animal facility of the Ministry of Healthcare of the Russian Federation Research Institute of Influenza according to the existing sanitary regulations.
  • mice were immunized abdominally with 20 ⁇ g of the recombinant fusion protein. The immunization was performed twice, with two weeks interval.
  • the mouse-adapted influenza virus strains A/California/07/2009 (H1N1) and A/PR/8/34 (H1N1) were used.
  • Virus titration for determination of a dose causing death of 50% of animals was performed on Balb/c mouse line (female mice, aged 6-7 weeks). Frozen virus was thawed, the mice lethal dose (causing 50% fatality) was estimated via introduction with ten-fold virus dilution (4 mice pro dilution). Mice were monitored for 14 days post introduction.
  • Virus titer was estimated using Reed and Muench mathematical technique. Mice were inoculated intranasally with the dosages of 1 LD/50 (dose causing 50% mortality in mice) and 5 LD/50 (dose causing 90% mortality in mice) at the rate of 50 ⁇ /mice under slight ether narcosis. After introduction, the animals were monitored for 14 days.
  • mice began to die on the sixth day after introduction.
  • the survival rate in the control group was 43%.
  • 100% survival rate was observed (Fig. 1).
  • Mice began to die on the sixth day after introduction.
  • the survival rate in the control group estimated 42%.
  • 100% survival rate was observed (Fig. 2).
  • Example 12 Development of polyvalent immune response to different influenza A and B virus strains via mouse immunization with the fusion protein.
  • mice In the present research Balb/c female mice aged 7-8 weeks (16-18 g weight) were used, which were received from the branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS (IBCh RAS) - Animals Breeding Center "Pushchino".
  • the laboratory animals were healthy and helminths-free (veterinary certificate 250 N° 0187942 of November 27, 2012).
  • the animals were kept in the animal facility of the Ministry of Healthcare of the Russian Federation Research Institute of Influenza according to the existing sanitary regulations.
  • mice were immunized abdominally with 20 ⁇ g/200 ⁇ l of the fusion protein. The immunization was performed twice, with two weeks interval. The animals were divided into experimental and control groups with 5-6 mice in each group.
  • Blood samples were taken from the tail vein from 5-6 mice out of each group two weeks after the second immunization. To obtain serum, blood was being incubated for 30 minutes at 37 °C. After clot formation, the samples were transferred on ice and cooled down for 1 hour, then centrifuged for 15 minutes at 400 g. Mice blood sera from each group were pooled and frozen at -20 °C.
  • Antibody titers in the sera of the immunized mice were determined via enzyme-linked immunosorbent assay, (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • ELISA was performed according to conventional technology. 96-well plates were used (Greiner, Germany), on which antigens from the strains A/California/07/09 (H1N1), A/PR/8/34 (H1N1), A/Perth/16/09 (H3N2), A/Chicken/Kurgan/20172005 (H5N1) were sorbed at a concentration of 2 ⁇ g/ml (in carbonate buffer, pH 9.5-9.6) and incubated over night at 4 °C.
  • Example 13 Capability of the antibodies formed after immunization of animals with inactivated influenza B virus to bind to the fusion protein.
  • rabbits from the genus chinchilla of 2 - 2.5 kg weight were used.
  • the rabbits were taken from the laboratory animal bank of Russian Academy of Medical Sciences, village Rappolovo, Leningrad . oblast.
  • the animals were kept in the animal facility of the Research Institute of Influenza, North- West Branch of the Russian Academy of Medical Sciences according to the existing sanitary regulations.
  • the capability of the antibodies formed after immunization of animals with inactivated influenza B virus to bind to the fusion protein was studied on rabbits.
  • the animals were immunized twice, with one month interval, subcutaneously with inactivated influenza virus B/Florida/04/ with Freund's adjuvant at the dosage of 10 9 PFU.
  • Blood was taken from the ear vein 1.5 months after the second immunization.
  • Titers of serum antibodies (IgG) against influenza virus B/Florida/04/06 and the fusion protein were estimated via ELISA (Anti Rabbit Ig-HRP conjugate, Sigma-Aldrich, A 6154, diluted 1 :5000). Blood serum from non- immunized rabbits was used as a negative control.
  • the results of the performed research show that antibodies against the surface proteins of influenza virus strain B/Florida/04/06 are capable of binding fusion protein; titers of antibodies against the fusion protein were 1 :204 000.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The problem to be solved: absence of safe efficient universal vaccine against influenza. The solution: The vaccine based on the fusion protein consisting of antigenic determinants of haemagglutinins of influenza A and B viruses and flagellin fragments functioning as safe adjuvant (SEQ ID NO:1) joined via flexible hinges is given which can be used for prophylaxis of influenza caused by existing influenza A and B strains as well as by possible reassortants. Safety, efficacy, polyvalence and preventive effect have been demonstrated. Usage of the present vaccine will allow to provide a universal protection against influenza.

Description

Polyvalent fusion protein vaccine against influenza
Field of the invention
The embodiment of present invention relates to molecular biology, biotechnology, preparative biochemistry, medicine, and can be used for prophylaxis of influenza, caused by existing influenza strains, as well as by possible reassortants.
Background of the invention
The term "fusion protein" refers to a protein, obtained by an expression of a recombinant DNA molecule, in which coding arrays of several different genes are bound to one reading frame. Annually, influenza virus affects from 5 to 15 percent of the population, causing acute respiratory diseases. Every year, vaccines against seasonal influenza are produced and widely used. However, a danger of pandemic spread of certain influenza virus strains with a new combination of genes exists. Such viruses can be more aggressive and cause a higher level of complications and fatalities. In 2009, an unfavorable situation took place, which was connected with an extension of the highly pathogenic influenza virus A(HlNl)pdm/09. Diseases were caused by the influenza virus with new antigenic determinants. In particular, specialists were worried about the fact that the new virus was a reassortant of viruses, circulating among both animals (swine) and humans. According to WHO, the infection ratio for humans, who had contact with contracted people, was 22% to 33% for A(H1N1) pdm/09. In comparison, the analog ratio for a seasonal influenza ranges from 5% to 15%.
The viral surface protein haemagglutinin (HA) is of particular interest in the light of development of the vaccines. HA is responsible for virus binding to cell receptors and in such a way for susceptibility to the disease. Mutations of HA usually lead to the increase of epidemiological and sometimes pandemic viral potential.
B-cell and T-cell response is being developed against antigenic determinants of viral proteins - the epitopes. Immunization against viral infections, namely influenza virus, based on usage of amino acid sequences represented by the viral epitopes, show great promise for the development of immune response against the virus and allows to create a universal vaccine for the prevention of both seasonal infection episodes and pandemic. Usage of antigenic determinants of different viral subtypes in one construct makes the production of the polyvalent vaccine easier and allows to create effective vaccines against new viral strains.
l It is essential to create a universal vaccine, which would be able to provide defense against the existing and possible reassortant influenza virus strains. The usage of vaccines, based on recombinant proteins, allows to avoid risks, which are connected even with the injection of inactivated viruses. A number of attempts has been made recently to create such a universal safe vaccine.
There is an invention, according to which the gene, coding for a multiepitopic haemagglutinin of the avian influenza virus, is used within the vector construct for the production of the recombinant multiepitopic vaccine in plants (RU 2008139004 A,
01.10.2008) . In the patent applications US 2009106864 (2009) and RU 2008139004 the authors used the consensus sequence of the avian influenza A virus haemagglutinin, codon optimized for the expression in plants. In the patent application JP2009102416 (2009) the authors used baculovirus constructs in the insect cells for the expression of haemagglutinin of influenza A and B viruses. The disadvantage of such approaches is the usage of protein (haemagglutinin) sequence from only one influenza virus subtype (H5N1). This narrows the spectrum of the vaccine activity. Moreover, the expression in plants and insect cells provides lower protein yields in comparison to the expression in E. coli.
Several fusion polypeptides are known which include a sequence with a high percentage of homology with the superficial HA-protein of the influenza A virus, containing five immunodominant antigenic epitopes (RU 92004487, 10.12.1992). One of the suggested applications for such polypeptides is to provide vaccines against corresponding antigens, for treatment and prophylaxis (including immunotherapeutic methods) in case of infection by such antigens. However, it is not specified, haemagglutinin of which subtypes is used. In the course of the development of the universal vaccine, the antigenic determinants of haemagglutinin of the influenza B virus as well should be taken into consideration, because the immunogenicity of the vaccine is limited by the strains, the sequences of which are used.
A polyvalent influenza vaccine is known which contains a polyvalent anti-influenza antigen, an adjuvant, an agent that provides the vaccine penetration, and an acceptable excipient (CN101450209, 31.12.2008). Antigens represented by HI -HI 6 and N1-N9 are declared as an antigenic component. A polyvalent influenza vaccine is also known consisting of surface viral proteins A/H1N1, A/H3N2, haemagglutinin of the B-type (CN101524538,
26.03.2009) , an adjuvant - glycerol or aluminum hydroxide. The usage of both an acceptable adjuvant and antigenic determinants in the fusion construct, as well as using single protein type - haemagglutinin will allow to simplify and reduce the cost for the production of the vaccine, inasmuch as it will be no more necessary to adjust the conditions and to control the quality of the component production.
A polyvalent vaccine is known which is based on the inactivated viruses. The active component is represented by antigens A/H1N1, H3N2, B, H5N1, and A (HlNl)pdm/09 (CN10173271 1, 31.12.2009). The listed antigens are extracted from the inactivated viruses, which means that the scaled-up production of the vaccine can be limited by possible problems, connected with the usage of viruses, especially influenza viruses. For instance, it is necessary to create appropriate working conditions, to handle easily transmitted highly pathogenic virus strains. Moreover, the listed antigens are separate proteins - the advantages of usage of a fusion construct are listed above.
The prototype of the invention is a mixture of flagella, containing at least four protein epitopes of influenza virus, which interact with human cells, whereat each one is being expressed separately in the flagellin of Salmonella (WO0032228, 30.11.1998). The listed epitopes refer to the group consisting of: (i) one haemagglutinin epitope, interacting with B cells, (ii) one epitope of haemagglutinin (HA) or of a nucleoprotein (NP), which can bind to MHC molecules for representation to receptors on the surface of the T helper cells and (iii) at least two nucleoprotein (NP) epitopes or a matrix protein (M) which are restricted by the MHC antigens that dominate by the Caucasians and bind to cytotoxic T lymphocytes (CTL).
In the present invention, flagellin FliC of Salmonella typhimurium fulfills an adjuvant function. Due to its interaction with Toll-like receptor-5 (TLR-5), FliC stimulates maturation of macrophages and dendritic cells, which results in induction of the immune response (Mc Dermott P. F.. High-affinity interaction between Gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect. Immun. - 2000. - V. 68. - p.:5525- 5529; Means T. . et al. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. - 2003. - V.170. - p. :5165-5175).
At the moment, flagellin is one of the most promising and well-studied new- generation adjuvants. The results of studies show that recombinant proteins, inoculated together with flagellin, possess higher immunogenic and antigenic properties. The responses to them are registered in shorter times and induce a more intense cellular and humoral immune response (Balaram, 2008).
The disadvantage of such invention lies in the complexity of the immunizing mixture. The usage of a fused protein, containing B and T cell epitopes of different influenza A and B virus subtypes, and flagellin, will trigger an intense immune response and lower the production costs. Therewithal, it is practical to use only components of flagellin. Two receptor-activating sites were detected in the terminal sites of flagellin (aa 79-1 17 and aa 08- 439) (Tonyia, 2001). TLR-5 is expressed on the cells of the innate immunity, epithelial, and endothelial cells (Sebastiani G. et al. Cloning and characterization of the murine Toll-like receptor 5(Tlr5) gene: sequence and mRNA expression studies in Salmonella-susceptibleMOLF/Eimice. Genomics. - 2000. - V. 64. - p.230-240; Zarember K.A. and Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J.Immunol. - 2002. - V.168. - p.554-561 ; Delneste. 2007). Taking this into consideration, it is practical to use mucosa for immunization, which will make the transport of the immunogen easier.
Description of the invention
The present invention embodies the vaccine based on highly purified fusion protein
(SEQ ID NO: l), which includes fragments of the proteins HI (281 - 461 aa), H3 (466 - 505 aa), H5 (510 - 549 aa) of the influenza A virus, as well as a fragment of influenza B viral haemagglutinin (554 - 593 aa), and flagellin components - FliCl (1-169 aa) and FHC2 (182- 276 aa) as adjuvants; the components are joined via flexible hinges. The represented protein fragments are conservative regions of haemagglutinins HI, H3, H5, and B. In course of naturally occurring infection, specific antibodies are produced against them, which cross-react with homolog epitopes amongst various strains of the influenza A and B viruses. The usage of the epitopes of several proteins will allow to increase the efficacy of the vaccine, and, due to the flexible hinges that join the epitopes, the correct three-dimensional structure of the protein will be provided, which will facilitate an adequate functioning of each epitope.
According to the chosen amino acid sequence, the appropriate nucleotide sequence (SEQ ID NO:2) was calculated by reference to the occurrence of the codons in the protein- coding genes of E. coli; at the same time, the codons were chosen by reference of the decrease of dG of the corresponding mRNA. The main technical result of usage of the invention is that the valency of the influenza vaccine increases: after introduction of the vaccine claimed in the present invention an immunity is developed against different subtypes of both influenza A and B viruses - against the existing and even against those subtypes that can appear as a result of reassortment of any other influenza virus strains. After the vaccine introduction, antibodies against the epitopes of haemagglutinin from different influenza virus strains are being produced in the body. Thus, an ability to produce antibodies in response to influenza virus infection is being developed. Thereafter, immune response upon the infection with any influenza virus will be developed faster, which will result in avoidance of the infection or the disease will be milder. Such approach will allow to eliminate the present disease.
The technical result of the codon optimization of the nucleotide sequence is in protein yields increase.
Therewithal, usage of flagellin components as a non-toxic adjuvant will increase the immune response, developed to the vaccine.
The technical result is also in lowering the price and speeding up of the vaccine production due to a single component (the fusion protein) production instead of a set of vaccine mixture (the prototype) components.
For production of the fusion protein - of the present invention, standard methods of molecular biology and microbiology can be used, which are familiar to a person having ordinary skill in the art. Such methods are described in scientific literature.
Description of the drawings
Figure 1. Dynamics of mice survival rate after infection with 1 LD/50 of virus A/PR/8/34 (H1N1). The days post infection are displayed on the horizontal axis, and the vertical axis shows the survival rate of mice in percents.
Figure 2. Dynamics of mice survival rate after infection with 1 LD/50 of virus A/California/07/09(H1N1). The days post infection are displayed on the horizontal axis, the survival rate of mice in percents - on the vertical axis.
Figure 3. Serum IgG against influenza B/Florida/04/06 virus. Serum IgG against the fusion protein. Serum dilution (the reciprocal value) is displayed on the horizontal axis, and the optical density at 450 nm - on the vertical axis.
Figure 4. Serum IgG against the fusion protein. Serum dilution (the reciprocal value) is displayed on the horizontal axis, and the optical density at 450 nm - on the vertical axis. The recombinant protein was entrapped at the concentration of 3 μg/ml. Example 1. Modeling of the fusion protein
The planned fusion polypeptide is a complex multidomain protein (6 domains: FliCl, FliC2, HI, H3, H5, B). For modeling of the multidomain protein following procedures were performed: estimation of the domain boarders, construction of a model of the full protein for estimation of the domains orientation, construction of models for each domain (using examples of 3D structures and ab initio-based modeling), docking of the models using the model of the full protein.
In the planned fusion polypeptide, two domains possessed prototypes and four thereof needed the ab initio-based modeling; furthermore during the ab initio-based modeling, flexible hinges between domains had to be formed.
For generation of realistic results in automatic mode, an I-Tasser algorithm was used, which had been considered the best in the last three protein-modeling competitions - CASPs (Critical Assessment of protein Structure Prediction). This analysis was being performed for five days. However, even by means of this strong algorithm, the generation of realistic data for the multidomain protein including the ab initio-based modeling of domains and their borders is not fully valid (70%).
For the purpose of generation of more exact data, the protein was split into used domains, and then their modeling was performed, using I-Tasser, followed by their docking. After all the steps mentioned above, the construction resulted that is shown in figures
1, 2.
The modeled fusion protein consists of 593 amino acid residues; its amino acid sequence is given - SEQ ID NO:l. Analysis of the amino acid sequence of this protein via ProtParam program (http://au.expasy.org/tools/protparam.html) has shown that the molecular weight of the fusion protein is 63.6 kDa, pi 6.2.
Example 2. Production of nucleotide sequence encoding the fusion protein.
The amino acid sequence of the fusion protein that included FliCl, FHC2, HI, H3, H5, B fragments was translated into the nucleotide sequence (1785 bp), which was then optimized for the expression in E. coli cells (SEQ ID NO:2). The synthesis of the present nucleotide sequence was performed via elongation of the overlapping oligonucleotides according to the described methods (Majumder, 1992). The oligonucleotides represented fragments of the fusion gene being 70 nucleotides long, containing overlapping regions of 20 nucleotides. The main primer requirements were as follows: their length should not exceed 60 nucleotides, while the fusionization sites should not be shorter than 20 nucleotides. Furthermore, there should not be long terminal G/C repeats. In certain cases, selection of the optimal primers was performed empirically via primer-template movement or primer length changing by 3-6 nucleotides. Altogether, for synthesis of the 1785 bp long fusion gene, 65 primers were used. The synthesized fragments (300 bp each) were extracted via gel-electrophoresis and cloned into the plasmid vector pGEM-T Easy. The cloning was performed using restriction sites Kpnl, SacII, EcoRV, BamHI or via blunt ends, as the case may be. After sequencing, the fragments were amplified and then joined into a nucleotide sequence of the fusion protein via polymerase chain reaction (PCR). After the final stage of the fusion gene synthesis via DNA fragment ligation, the artificial gene was cloned into the pGEM-T vector via Kpnl and Sad restriction sites. The produced gene was flanked by additional restriction sites: EcoRI at the 5' end and Xhol at the 3' end. Next, the artificial gene was recloned into the expression vector pET24a via EcoRI and Xhol restriction sites.
Example 3. Production of plasmid DNA encoding the fusion protein. According to the methods described in the example 2, a nucleotide sequence was obtained for the purpose of production of the influenza vaccine.
The resulting gene was cloned into the pET24a plasmid for the purpose of subsequent expression in E. coli cells. Therefore, ligation of the gene and the pET24a vector via appropriate buffer and ligase was performed. The reaction was being performed at +20 °C for 2 hours.
The mixture was being warmed up at +95 °C for 10 min. Afterwards, saults were removed via dialysis through nitrocellulose membrane filters with the pore size of 0.025 μηι (Millipore, USA). The dialysis was being performed against solution containing 0.5 mM EDTA in 10% glycerol for 10 min. Example 4. Production of the E. coli strain for amplification of the plasmid DNA containing the fusion gene.
According to the methods described in the example 3, a nucleotide sequence of the gene was produced for the purpose of creation of the influenza vaccine, and then it was cloned into the pET24a vector. The E. coli cells of the strain DHIOB/R (Gibko BRL, USA) possessing following genotype: F-mcrA A(mrr-hsdRMS-mcrBC) (p80dlacZAM 15 AlacX74 deoR recAl endAl araD139 A(ara, leu)769 galU galKX- rpsL nupG were transformed with the resulted plasmid via electroporation.
After transformation, the cells were being incubated in SOC medium (2% bacto- tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04, 20 mM glucose) for 40 min at +37°C.
After screening of the E. coli cells for possessing the plasmid - in the selective medium containing LB-agar and 100 μg/ml kanamycin, - the appropriate colonies of E. coli cells were sampled to obtain the E. coli strain for the subsequent amplification of the plasmid DNA containing the fusion gene.
The plasmid DNA was extracted from the grown clones via Wizard Minipreps DNA Purification System kit (Promega, USA).
The purified plasmid DNA was analyzed via restriction assay and sequencing. In course of research, the clones were sampled, which contained DNA fragments of required size in their plasmids. Next, such plasmids were extracted for the subsequent induction of the gene expression.
Example 5. Obtaining the E. coli strain producing the fusion protein.
According to the methods described in the example 4, the nucleotide sequence of the protein was obtained for the purpose of production of the influenza vaccine and then was cloned into the pET24a plasmid; the resulted plasmid was amplified in the E. coli cells of the strain DH10B/R and then extracted.
For the expression of the protein, the E. coli cells of the strain BL21 Star (DE3)
(Invitrogen, USA) with following genotype: F- ompT hsdSB (rB-mB-) gal dcm rnel31 (DE3) containing De3 lysogen and rnel31 mutation in genome were used. The mutant rrce-gene
(rnel31) encodes a short version of RNase E, so that intracellular mRNA degradation is reduced and its fermentative stability is increased. The Ion- and ompr-mutations in protease genes allow obtaining high yields of non-proteolyzed recombinant proteins.
The E. coli cells of the strain BL21 with the genotype F- ompT hsdSB (rB-mB-) gal dcm mel31 (DE3) were prepared as following. The cells were being incubated at +37 °C overnight in 5 ml L-broth, containing 1% tryptone, 1% yeast extract and 1% sodium chloride. The culture was diluted 50-100 fold in fresh L-broth and was being cultivated in a shaking incubator at +37 °C until the optical density of 0.2-0.3 at 590 nm was measured. After having reached 0.3 OD, the culture was diluted in the fresh L-broth until 0.1 OD and was being cultivated for 30 min. The culture in the volume of 100 ml was transferred to a sterile centrifuge tube, and cell pelleting was being performed at +4 °C, 5000 g for 10 min. The supernatant was discarded, and the cells were resuspended in deionized water to the initial volume under subsequent centrifuging. The washing steps were repeated three times. After washing, the cell pellet was resuspended in a small volume of deionized water and the suspension was being centrifuged for 30 sec at 5000 rpm in a microcentrifuge. The transformation of the competent cells was performed via electroporation.
Therefore, 1 μΐ of plasmid DNA was added to 12 μΐ of competent cells, and the suspension was mixed. The subsequent electroporation was performed via pulse generator GVI-1 (St. Petersburg State Polytechnical University, St. Petersburg) in sterile chambers at 10 kV/cm for 4 msec. After transformation, the cells were being incubated in SOC medium (2% bacto tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04, 20 mM glucose) for 40 min at +37 °C. 10-100 μΐ cell suspension was transferred to selective LB medium (Gibco BRL, USA) containing kanamycin (100 μg/ml) for selection of the clones with the plasmids (producer strains). The plasmid obtained after transformation of the competent E. coli cells provided a high level of expression of the encoded recombinant protein.
Example 6. Production of the fusion protein for the creation of the influenza vaccine in E. coli cells via induction of protein synthesis by 0.2% lactose according to Studier method.
According to the methods described in the example 5, the nucleotide sequence of the fusion protein for the creation of the influenza vaccine was obtained and cloned in the pET24a plasmid; the obtained plasmid was amplified in E: coli cells of the strain DH10B/R, extracted, and E. coli cells of the strain BL21 were transformed thereby for the purpose of induction of the target gene expression.
For the purpose of cultivation of the obtained producer strains, standard agarized LB medium containing kanamycin (100 μg/ml) and 1% glucose for blocking of nonspecific expression was used.
The expression was induced after the cell culture had reached the optical density of 0.6-0.8 at 600 nm. 0.2% lactose was used as inductor (Studier, 2005).
For autoinduction of the expression according to the Studier's method (Studier, 2005), PYP-5052 medium was used, containing 1% peptone (Gibco, USA), 0.5% yeast extract (Gibco, USA), 50 mM Na2HP04, 50 mM K2HP04, 25 mM (NH4)2S04, 2 mM MgS04, 0.5% glycerol, 0.05% glucose and 0.2% lactose.
A single producer strain colony was inoculated into PYP-5052 medium, containing kanamycin (100 μg/ml). The fermentation was being performed at +37 °C in a thermostatic shaker at 250 rpm for 20 hours until no significant change in the OD600 per hour measured. An aliquot of the cells was taken for the purpose of expressional analysis of the gene encoding the vaccine protein. The expressional analysis was performed via polyacrylamide gel electrophoresis (PAGE). The rest of the biomass was pelleted in the centrifuge at 9000 g.
The protein was extracted from the E. coli cells via cell lysis. The cells were resuspended in the lysis buffer, containing 20 mM tris-HCl pH 7.5, 5 mM EDTA, and 1 mM phenoxymethylsulfonylfluoride (PMSF), on 1 g cells per 5-7 ml buffer basis. The cell suspension was exposed to ultrasound 7 times for 30 sec at a 30 sec interval (22 kHz). The lysate was being centrifuged for 10 min at +4 °C, 5000 g. The supernatant was discarded, and the pellet was resuspended in 1 M urea solution on 10 ml per 1 g cells basis by intensive mixing. The centrifuge step was repeated. The supernatant was discarded, and the pellet was resuspended in 2 M urea solution of the same volume. The centrifuge step was repeated. The supernatant was discarded.
According to the SDS-Page (Polyacrylamide Gel Electrophoresis with Sodium Dodecyl Sulfate) data the obtained product contained approximately 98% of the fusion protein at concentration of 1 mg/ml.
The extraction and purification conditions were adjusted experimentally and can vary to some extent that a person of ordinary skill in the art familiar with. Example 7. Obtention of preparation of purified fusion protein
MgCl2 was added to the fusion protein solution to reach the concentration of 6 mM. The fusion protein was purified via Immobilized-Metal Affinity Chromatography (IMAC) using Ni-NTA Sepharose. The capture by this sorbent is performed due to 6 histidine residues on the N-terminus of the obtained recombinant protein. The protein solution filtering was performed via PVDF filter with a pore diameter of 0.22 μπι. To the so obtained filtrate the sorbing agent - Ni-NTA sepharose - was given, which was equilibrated with refolding buffer, making allowance of the fact that 1 ml of the sorbent can bind not more than 40 mg of protein. The capture was being performed for 2 hours. The sorbent was pelleted via centrifugation and transferred to a gravity chromatography column, containing 2 ml of the sorbent.
The step gradient elution was performed with 20 - 300 mM imidazole by 50% of the previous concentration at each step, using eluting solution at a volume of 5-20 fold of the column volume. The yield and purity of the protein was controlled via disc electrophoresis and Bradford protein assay.
For determination of the endotoxin content, standard stock endotoxin solution with the defined potency of 4000 EU was prepared. The produced solution was stable for at least two weeks, when preserved at +4 °C. A two-fold serial dilution was prepared in sterile polystyrene tubes, using endotoxin-free water. The tubes were sealed with endotoxin-free parafilm. A five-fold and - after the preparatory endotoxin content evaluation - a two-fold serial dilution of the sample were prepared. The sample, water, 100 μΐ of endotoxin, and, at last, 100 μΐ of LAL-reactive were put on the bottom of each eppendorf tube. The mixture was being incubated for 1 hour at 37°C in a water bath. The results were estimated by means of presence or absence of a firm clot on the bottom of the inverted tube. The absence of factors that inhibit clot formation in the analyzed sample was shown.
The gel clot was formed at a 1/8 sample dilution, it means that, taking into consideration the method sensitivity of 0.03 EU/ml, the sample with the concentration of 50 μg/ml contained less than 100 EU.
The conformation of the recombinant fusion protein during its biosynthesis in E. coli was determined via polyacrylamide discontinuous electrophoresis of the disrupted by sonication E. coli cells, after the induction of the expression. In addition, both pellet and supernatant, formed after sedimentation of the cell lysate, were analyzed. Densitometric analysis demonstrated that 100% of the recombinant protein, synthesized in E. coli producer strain, was accumulated in the supernatant, i.e. in the soluble fraction.
Cultivation of bacteria at different temperatures: 20 °C, 30 °C and 37 °C, did not affect protein solubility.
After autoinduction of the expression in E. coli with 0.2% lactose and subsequent polyacrylamide disc electrophoresis of the cell lysates, the densitometric analysis of target protein expression in E. coli was performed. The densitometric analysis demonstrated that the fusion protein accumulates and amounts 43% of total cellular protein content.
The obtained expression level did not change in the producer strain for 6 passages, which indicates a stable expression of the analyzed gene.
Example 8. Production of the recombinant fusion protein via cultivation of E. coli cells with continuous nutrient supply (preferred nutrients: glucose and yeast extract). A fed-batch culture of Escherichia coli strain was used for the purpose of production of the fusion protein. This method is preferred, when it is necessary to avoid substrate limitation and its negative consequences. Thereby, a substrate or any other essential components are being supplied either continuously, or in response to sensor signals. For the purpose of optimization of the yields of product being secreted in the medium, it is important to increase the biosynthetic capabilities of the bacterial cells, while the cultivation mode will extend the second growth phase and increase the yields of extracellular metabolites. This method can be used in case of a potentially toxic substrate (recombinant proteins are toxic for the E. coli cells), as its concentration in the medium will be kept at a low level.
Due to overcome of catabolite repression of the product synthesis, the speed of substrate uptake can be limited by the speed of its transport.
Fed-batch culture appeared to be the most effective way to achieve a high cell density and high productivity.
The E. coli strain was passaged on the angular EDTA-containing agar under sterile conditions and was being incubated in the thermostat for 5 days. To obtain the inoculate, the culture was washed from the agar, passaged to a liquid EDTA-containing medium with, and cultivated for 3-4 days. Next, 10 ml inoculate was passaged into 750-ml flasks, containing 200 ml of sterile liquid medium, and cultivated in a thermostatic shaker at 150-200 rpm, 28 °C - 30 °C for 10 days.
Gel growth medium was used to obtain fresh culture of the strain.
The liquid growth medium was used to obtain the seed material and for periodic cultivation.
Preparation of the liquid growth medium
1) MgSO4*7 H20 10 ml/1
2) CaCl2*2 H20 20 ml/1
3) KH2P04 + NaH2P04* 12 H20 10 ml/1
4) EDTA 10 ml/l
5) Microelements 1 ml/1
(pH adjusted to 4,2) + 5.6 g/1 EDTA: FeCl2*4 H20 1.5 g/1 H3B03 0.06 g/1 MnCl2*6 H2O 0.1 g/1 CaCl2*6 H20 0.12 g/1 ZnCl2 0.07 g/1 NiCl2*6 H20 0.025 g/1 CuCl2*2 H20 0.015 g/1 Na2MoCl4 0.025 g/1
6) Vitamins Pyridoxine 20 mg Thiamine 10 mg Riboflavin 10 mg Nicotinic acid 10 mg 4-Aminobenzoic acid 10 mg Alpha lipoic acid 10 mg Nicotinamide 10 mg Vitamin B 12 10 mg
Biotin 4 mg Folic acid 4 mg
All components were dissolved in 200 ml of water, sterilized at 0.5 atm for 30 min, and added to a liquid nutrient broth medium at the rate of 1 ml/1. The compounds of the growth medium were weighted on technical and analytical balances and dissolved in distilled water. According to the previous experience, we prepared growth media out of presterilized concentrated solutions.
The gel growth medium was produced both as a liquid and with 3% agar.
The optical density (OD600) of the E. coli cell culture was 9. The cells were sedimented via centrifugation at 13000 g for 6 min at 10 °C. The cell pellet was weighted; its weight was 2.1 g.
The cells were resuspended in 30 ml buffer (50 mM TrisHCl, 50 mM EDTA, 20 mM L-cysteine, pH 8.6) and disrupted by ultrasound (sonication time - 10 min, impulse time - 30 sec, pause between the impulses - 30 sec, amplitude - 70%). After the cell breakage, the inclusion bodies were pelleted under centrifugation at 30000 g for 20 min at 10 °C; the wet weight of the inclusion bodies was 1.45 g. the pelleted inclusion bodies were washed with several buffers according to the following scheme:
1. The pellet containing inclusion bodies was resuspended in 10 ml (the last wash
- 15 ml) of washing buffer
2. The resuspended inclusion bodies were mixed on a horizontal shaker for 1 hour at a room temperature
3. The inclusion bodies were pelleted via centrifugation at 30000 g for 20 min at
10 °C
After five washing steps, the wet weight of the inclusion bodies was 0.7 g. For the purpose of protein solubilization out of the inclusion bodies, 18 ml of solution (9 M urea, 2 mM EDTA, 50 mM TrisHCl, pH 8.6) was used. The solubilized inclusion bodies were being centrifuged at 30000 g for 20 min at 10 °C. The developed supernatant was transferred in to the new falcons and was used for the refolding. The refolding step was performed as follows: the solubilized inclusion bodies were
10-fold diluted in the refolding buffer at +4 °C dropwise. MgCl2 was added to the refolded protein until 6 mM. Protein purification was performed via Immobilized-Metal Affinity Chromatography (IMAC) using Ni-NTA Sepharose. The protein solution was filtered via PVDF filter with a pore diameter of 0.22 μπι. To the so obtained filtrate the sorbing agent - Ni-NTA sepharose - was given, which was equilibrated with refolding buffer, taking into consideration the fact that 1 ml of sorbent can bind not more than 40 mg of protein. The capture was being performed for 2 hours. The sorbent was pelleted via centrifugation and was given at a minimal volume onto a gravity chromatography column containing 2 ml of sorbent.
The step gradient elution was performed with 20 - 300 mM imidazole (20, 40, 100, 150, 200 H 300 mM), whereas at each step the volume of the eluting solution was 10 fold of the column volume.
In this way, 41 mg of fusion protein with the purity of 97% was obtained.
Example 9. Production of the fusion protein, being purified before dilution, and removal of soluble cell components including DNA, RNA, proteins, lipopolysaccharides via washing with buffer solution, containing a guanidine hydrochloride detergent.
Upon fermentation, cell breakage, and washing of the inclusion bodies (see Example 8), protein was solubilized in 18 ml of solution (8 M GuHCl, 2 mM EDTA, 50 mM TrisHCl, pH 8.6), containing guanidinium chloride. The solubilized inclusion bodies were pelleted under centrifugation at 30000 g for 20 min at 10°C. The obtained supernatant was transferred to new falcons and used for refolding.
Next, refolding and purification of the recombinant protein were performed (see Example 8). As a result of purification, 41 mg of the fusion protein was obtained, with a purity rate of 98%. Example 10. Determination of immunogenicity of the obtained protein.
An immunogenicity test of the obtained protein was performed. Immunogenicity is a capability of an antigen to initiate production of effectors that neutralize antigenic foreignness by immune system. In order to induce immune response, an antigen should be immunogenic. The point to be emphasized is that immunogenicity is a complex feature, which depends on the properties of the antigen itself, the way of its penetration, and the way of immunization.
Mice were immunized abdominally with 20 μg of the fusion protein. The immunization was performed twice, spaced two weeks apart. The animals were divided into experimental and control groups with 5-6 mice in each group. Blood samples were taken from the tail vein from 5-6 mice out of each group two weeks after the second immunization. To obtain serum, blood was incubated for 30 minutes at 37 °C. After clot formation, the samples were transferred on ice, cooled down for 1 hour, and then centrifuged for 15 minutes at 400 g. Mice blood sera from each group were pooled and frozen at -20 °C. Antibody titers in the sera of the immunized mice were determined via enzyme-linked immunosorbent assay, (ELISA). ELISA was performed according to conventional technology. 96-well plates were used (Greiner, Germany), on which the fusion protein was sorbed (in carbonate buffer, pH 9.5-9.6) and incubated over night at 4 °C.
The fusion protein was denaturated as follows. To the protein sample a detergent Tween-20 was being added, until the end-concentration of 1% (w/v) was reached. Next, the sample was being incubated in a water bath for 1 hour at 37 °C. After the incubation step, the sample was being centrifuged for 1 hour at 200 °C and 2000 g, and supernatant, containing the fusion protein, was taken. The detergent was liquidated via Detergent-OUTtmMicro Kit (Millipore); the detergent-free sample was being concentrated on the SpeedVac until the original volume. Additional treatment of the product was performed with 8M urea and dithiothreitol (0.02M) upon subsequent dialysis over night against carbonate buffer (pH=8.5).
The microtiter plates were being treated by blocking buffer (0.01 M PBS, pH=7.2-7.4 with 5% FCS) for 1 hour at room temperature and then washed three times with PBS containing Tween-20. 100 μΐ two-fold serum dilutions in blocking buffer (beginning with 1 :200) were given to plate wells and incubated for 1 hour at room temperature. The serum was analyzed in duplicate. As a conjugate, polyclonal rabbit anti-mouse radish peroxidase- conjugated IgG antibodies (Abeam, UK), diluted 1 :8000, were used. TMB was used as a substrate. Detection was performed at 450 nm. The endpoint titer was the highest dilution that gives an optical density of 2 standard deviations above negative control - serum of non- immunized mice at the same dilution.
The results show a high immunogenicity of the obtained protein. After immunization with the fusion protein, antibodies to the antigen were detected, titer is 51 200.
Therefore, development of a strong immune response in mice immunized with the fusion protein was demonstrated.
Example 11. Protective effect of the vaccine based on the fusion protein against different influenza virus strains.
In the present research 30 Balb/c female mice aged 7-8 weeks (16-18 g weight) were used, which were received from the branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS (IBCh RAS) - Animals Breeding Center "Pushchino". The laboratory animals were healthy and helminths-free (veterinary certificate 250 N° 0187942 of November 27 2012). The animals were kept in the animal facility of the Ministry of Healthcare of the Russian Federation Research Institute of Influenza according to the existing sanitary regulations.
Mice were immunized abdominally with 20 μg of the recombinant fusion protein. The immunization was performed twice, with two weeks interval. To analyze protectivity of the fusion protein on the model of lethal influenza infection, the mouse-adapted influenza virus strains A/California/07/2009 (H1N1) and A/PR/8/34 (H1N1) were used. Virus titration for determination of a dose causing death of 50% of animals was performed on Balb/c mouse line (female mice, aged 6-7 weeks). Frozen virus was thawed, the mice lethal dose (causing 50% fatality) was estimated via introduction with ten-fold virus dilution (4 mice pro dilution). Mice were monitored for 14 days post introduction. Virus titer was estimated using Reed and Muench mathematical technique. Mice were inoculated intranasally with the dosages of 1 LD/50 (dose causing 50% mortality in mice) and 5 LD/50 (dose causing 90% mortality in mice) at the rate of 50 μΐ/mice under slight ether narcosis. After introduction, the animals were monitored for 14 days.
Mice began to die on the sixth day after introduction. The survival rate in the control group was 43%. In the experimental group 100% survival rate was observed (Fig. 1). Mice began to die on the sixth day after introduction. The survival rate in the control group estimated 42%. In the experimental group 100% survival rate was observed (Fig. 2).
Example 12. Development of polyvalent immune response to different influenza A and B virus strains via mouse immunization with the fusion protein.
In the present research Balb/c female mice aged 7-8 weeks (16-18 g weight) were used, which were received from the branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS (IBCh RAS) - Animals Breeding Center "Pushchino". The laboratory animals were healthy and helminths-free (veterinary certificate 250 N° 0187942 of November 27, 2012). The animals were kept in the animal facility of the Ministry of Healthcare of the Russian Federation Research Institute of Influenza according to the existing sanitary regulations.
Mice were immunized abdominally with 20μg/200μl of the fusion protein. The immunization was performed twice, with two weeks interval. The animals were divided into experimental and control groups with 5-6 mice in each group.
Blood samples were taken from the tail vein from 5-6 mice out of each group two weeks after the second immunization. To obtain serum, blood was being incubated for 30 minutes at 37 °C. After clot formation, the samples were transferred on ice and cooled down for 1 hour, then centrifuged for 15 minutes at 400 g. Mice blood sera from each group were pooled and frozen at -20 °C.
Antibody titers in the sera of the immunized mice were determined via enzyme-linked immunosorbent assay, (ELISA). ELISA was performed according to conventional technology. 96-well plates were used (Greiner, Germany), on which antigens from the strains A/California/07/09 (H1N1), A/PR/8/34 (H1N1), A/Perth/16/09 (H3N2), A/Chicken/Kurgan/05/2005 (H5N1) were sorbed at a concentration of 2μg/ml (in carbonate buffer, pH 9.5-9.6) and incubated over night at 4 °C.
The fusion protein was denaturated as follows. Detergent Tween-20 was being added to the protein sample until the end-concentration of 1% (w/v) was reached. Next, the sample was being incubated in a water bath for 1 hour at 37 °C. After the incubation step, the sample was being centrifuged for 1 hour at 200 °C and 2000 g, and supernatant containing the fusion protein was taken. The detergent was liquidated via Detergent-OUTtmMicro Kit (Millipore); the detergent-free sample was being concentrated on the SpeedVac until the original volume. Additional treatment of the product was performed with 8M urea and dithiothreitol (0.02M) upon subsequent dialysis over night against carbonate buffer (pH=8.5).
* The microtiter plates were being treated by blocking buffer (0.01M PBS, pH=7.2-7.4 with 5% FCS) for 1 hour at room temperature and then washed three times with PBS containing Tween-20. 100 μΐ two-fold serum dilutions in blocking buffer (beginning with 1 :200) were given to plate wells and incubated for 1 hour at room temperature. All sera were analyzed in duplicate. Polyclonal rabbit anti-mouse radish peroxidase-conjugated IgG antibodies (Abeam, UK), diluted 1 :8000, were used as a conjugate. TMB was used as a substrate. Detection was performed at 450 nm. The endpoint titer was the highest dilution that gives an optical density of 2 standard deviations above negative control - serum of non- immunized mice at the same dilution.
Table 1. Titers of serum antibodies (IgG) after dualfold immunization of mice with fusion protein.
Figure imgf000020_0001
In course of immunization with the fusion protein, antibodies against all examined strains of influenza A virus at the rates of 1 :3200 in the case of H3N2 A/Perth 16/09 up to 1 :51200 in the case of H1N1 A/California/07/09 were found in murine blood.
Thus, development of polyvalent immune response against different strains of influenza A and B virus in mice immunized with the fusion protein was demonstrated.
Example 13. Capability of the antibodies formed after immunization of animals with inactivated influenza B virus to bind to the fusion protein.
In the present research, rabbits from the genus chinchilla of 2 - 2.5 kg weight were used. The rabbits were taken from the laboratory animal bank of Russian Academy of Medical Sciences, village Rappolovo, Leningrad . oblast. The animals were kept in the animal facility of the Research Institute of Influenza, North- West Branch of the Russian Academy of Medical Sciences according to the existing sanitary regulations.
The capability of the antibodies formed after immunization of animals with inactivated influenza B virus to bind to the fusion protein was studied on rabbits. The animals were immunized twice, with one month interval, subcutaneously with inactivated influenza virus B/Florida/04/ with Freund's adjuvant at the dosage of 109 PFU. Blood was taken from the ear vein 1.5 months after the second immunization. Titers of serum antibodies (IgG) against influenza virus B/Florida/04/06 and the fusion protein were estimated via ELISA (Anti Rabbit Ig-HRP conjugate, Sigma-Aldrich, A 6154, diluted 1 :5000). Blood serum from non- immunized rabbits was used as a negative control. The results of the performed research show that antibodies against the surface proteins of influenza virus strain B/Florida/04/06 are capable of binding fusion protein; titers of antibodies against the fusion protein were 1 :204 000.
Titers of serum antibodies (IgG) against influenza virus strain B/Florida/04/06 and the fusion protein were estimated via ELISA (Anti Rabbit Ig-HRP conjugate, Sigma-Aldrich, A 6154, diluted 1 :5000). The results are shown on the Fig.3 and Fig.4. The titers of antibodies in ELISA against influenza virus strain B/Florida/04/06 and the fusion protein were 409'600 and 204' 800, correspondingly. Thus, immunologic polyvalence of the fusion protein against influenza A and B viruses has been demonstrated.

Claims

Claims
1. The polyvalent influenza vaccine, based on the fusion protein (SEQ ID NO:l) that contains fragments of the proteins HI (281 - 461 aa), H3 (466 - 505 aa), H5 (510 - 549 aa) of influenza A virus, as well as the fragment of haemagglutinin of influenza B virus (554 - 593 aa), and flagellin components - FliCl (1-169 aa) and FliC2 (182-276 aa) as adjuvant, which are joined via flexible hinges.
2. The polyvalent influenza vaccine according to claim 1, characterized by the fact that the fusion protein is encoded in the codon-optimized for expression in E.coli cells nucleotide sequence SEQ ID NO:2.
3. The polyvalent influenza vaccine according to claim 1, characterized by being produced as a result of creation of the recombinant DNA encoding the fusion protein according to claim 1 , insertion of this DNA in a vector construct with the high level of its expression in the bacterial cells of Escherichia coli, transfer of this vector construct into bacterial cells of Escherichia coli, production of the fusion protein in the mentioned organism, its extraction, purification, and mixing with a physiologically acceptable excipient.
PCT/RU2014/000096 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza WO2014126510A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP14751295.8A EP2956168B8 (en) 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza
CN201480008848.7A CN104994871B (en) 2013-02-15 2014-02-14 For the multivalent fusion proteins vaccine of influenza
EA201500770A EA027463B1 (en) 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza
MX2015010623A MX362420B (en) 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza.
UAA201508723A UA115895C2 (en) 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza
US14/768,107 US9480737B2 (en) 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza
CUP2015000083A CU24288B1 (en) 2013-02-15 2014-02-14 FUSION PROTEIN POLIVALENT VACCINE AGAINST INFLUENZA
HK16104349.2A HK1216499A1 (en) 2013-02-15 2016-04-15 Polyvalent fusion protein vaccine against influenza

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013107777/10A RU2531235C2 (en) 2013-02-15 2013-02-15 Hybrid protein-based polyvalent influenza vaccine
RU2013107777 2013-02-15

Publications (2)

Publication Number Publication Date
WO2014126510A2 true WO2014126510A2 (en) 2014-08-21
WO2014126510A3 WO2014126510A3 (en) 2014-10-16

Family

ID=51354649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2014/000096 WO2014126510A2 (en) 2013-02-15 2014-02-14 Polyvalent fusion protein vaccine against influenza

Country Status (11)

Country Link
US (1) US9480737B2 (en)
EP (1) EP2956168B8 (en)
CN (1) CN104994871B (en)
CU (1) CU24288B1 (en)
EA (1) EA027463B1 (en)
HK (1) HK1216499A1 (en)
MX (1) MX362420B (en)
NI (1) NI201500109A (en)
RU (1) RU2531235C2 (en)
UA (1) UA115895C2 (en)
WO (1) WO2014126510A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2757013C2 (en) * 2017-12-19 2021-10-08 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Recombinant anti-influenza vaccine with wide range of protection and method for its preparation
IL305911B1 (en) 2018-03-19 2024-09-01 Novavax Inc Multivalent influenza nanoparticle vaccines

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU92004487A (en) 1991-12-11 1996-07-27 Американ Хоум Продактс Корпорейшн DNA, POLIPEPTID, VACCINE, VECTOR, MICROORGANISM, INSECTED CELL, REAGENT, METHODS OF TREATMENT AND PREVENTION, METHOD OF DETECTING ANTIGENES
WO2000032228A2 (en) 1998-11-30 2000-06-08 Yeda Research And Development Co. Ltd. Peptide-based vaccine for influenza
US20090106864A1 (en) 2006-06-16 2009-04-23 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
JP2009102416A (en) 2009-02-04 2009-05-14 Protein Sciences Method for producing influenza hemagglutinin polyvalent vaccine
CN101450209A (en) 2008-12-31 2009-06-10 中国人民解放军军事医学科学院微生物流行病研究所 Transdermal immune influenza multivalent vaccine and preparation method thereof
CN101524538A (en) 2009-03-26 2009-09-09 成都康华生物制品有限公司 Influenza-pandemic influenza bivalent combined vaccine and preparation method thereof
RU2008139004A (en) 2008-10-01 2010-04-10 Биологический факультет Московского государственного университета им. М.В. Ломоносова (RU) GENE OF A VACCINE ARTIFICIAL PROTEIN PRODUCING IN A PLANT A RECOMBINANT MULTI-EPITOPIC VACCINE ON THE BASE OF HEMAGAGLUTININ VIRUS INFLUENZA BIRDS
CN101732711A (en) 2009-12-31 2010-06-16 中国人民解放军军事医学科学院微生物流行病研究所 Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101394864A (en) * 2006-03-07 2009-03-25 法克斯因内特公司 Compositions that include hemagglutinin, methods of making and methods of use thereof
RU2358981C2 (en) * 2007-08-07 2009-06-20 Центр "Биоинженерия" Российской Академии Наук Universal avian influenza virus vaccine
JP2012521786A (en) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ Influenza virus vaccine and use thereof
US8513006B2 (en) * 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU92004487A (en) 1991-12-11 1996-07-27 Американ Хоум Продактс Корпорейшн DNA, POLIPEPTID, VACCINE, VECTOR, MICROORGANISM, INSECTED CELL, REAGENT, METHODS OF TREATMENT AND PREVENTION, METHOD OF DETECTING ANTIGENES
WO2000032228A2 (en) 1998-11-30 2000-06-08 Yeda Research And Development Co. Ltd. Peptide-based vaccine for influenza
US20090106864A1 (en) 2006-06-16 2009-04-23 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
RU2008139004A (en) 2008-10-01 2010-04-10 Биологический факультет Московского государственного университета им. М.В. Ломоносова (RU) GENE OF A VACCINE ARTIFICIAL PROTEIN PRODUCING IN A PLANT A RECOMBINANT MULTI-EPITOPIC VACCINE ON THE BASE OF HEMAGAGLUTININ VIRUS INFLUENZA BIRDS
CN101450209A (en) 2008-12-31 2009-06-10 中国人民解放军军事医学科学院微生物流行病研究所 Transdermal immune influenza multivalent vaccine and preparation method thereof
JP2009102416A (en) 2009-02-04 2009-05-14 Protein Sciences Method for producing influenza hemagglutinin polyvalent vaccine
CN101524538A (en) 2009-03-26 2009-09-09 成都康华生物制品有限公司 Influenza-pandemic influenza bivalent combined vaccine and preparation method thereof
CN101732711A (en) 2009-12-31 2010-06-16 中国人民解放军军事医学科学院微生物流行病研究所 Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MC DERMOTT P.F.: "High-affinity interaction between Gram-negative flagellin and a cell surface polypeptide results in human monocyte activation", INFECT. IMMUN., vol. 68, 2000, pages 5525 - 5529, XP002383725, DOI: doi:10.1128/IAI.68.10.5525-5529.2000
MEANS T.K. ET AL.: "The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells", J.IMMUNOL., vol. 170, 2003, pages 5165 - 5175
SEBASTIANI G. ET AL.: "Cloning and characterization of the murine Toll-like receptor 5(Tlr5) gene: sequence and mRNA expression studies in Salmonella-susceptibleMOLF/Eimice", GENOMICS, vol. 64, 2000, pages 230 - 240
See also references of EP2956168A4
ZAREMBER K.A.; GODOWSKI P.J.: "Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines", J.IMMUNOL., vol. 168, 2002, pages 554 - 561

Also Published As

Publication number Publication date
CN104994871A (en) 2015-10-21
MX362420B (en) 2019-01-14
HK1216499A1 (en) 2016-11-18
NI201500109A (en) 2015-10-27
EP2956168A2 (en) 2015-12-23
CU20150083A7 (en) 2016-07-29
US9480737B2 (en) 2016-11-01
MX2015010623A (en) 2015-12-15
WO2014126510A3 (en) 2014-10-16
US20150374814A1 (en) 2015-12-31
RU2531235C2 (en) 2014-10-20
EP2956168A4 (en) 2016-09-14
EA201500770A1 (en) 2015-12-30
CN104994871B (en) 2018-01-26
RU2013107777A (en) 2014-08-20
CU24288B1 (en) 2017-12-08
EA027463B1 (en) 2017-07-31
EP2956168B1 (en) 2018-07-25
EP2956168B8 (en) 2019-01-23
UA115895C2 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
Hou et al. The advances in brucellosis vaccines
Ma et al. Vaccination of chickens with DNA vaccine encoding Eimeria acervulina 3-1E and chicken IL-15 offers protection against homologous challenge
Deng et al. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge
US9345757B2 (en) Chimeric protein vaccine against pneumonia caused by Streptococcus pneumoniae
Zheng et al. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses
EP3715359A1 (en) Cd4 helper t cell epitope fusion peptide and vaccine therewith
Tebianian et al. Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70
Chen et al. Design of bacterial inclusion bodies as antigen carrier systems
EP2956168B1 (en) Polyvalent fusion protein vaccine against influenza
KR20140146803A (en) Recombinant Protein Comprising Epitope of Avian reovirus sigma C Protein and Antibody thereto
Yin et al. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine
WO2012126149A1 (en) Mycobacterium tuberculosis fusion protein and its preparation method and use thereof
CN109207502A (en) Porcine mycoplasmal pneumonia and porcine circovirus 2 type recombinant protein and prepare bigeminy vaccine
WO2012089748A1 (en) Canine babesiosis vaccine antigen
RU2539913C2 (en) Vaccine for prevention and treatment of rotaviral infection containing hybrid protein as active agent (versions)
AU2017366410B2 (en) Reconstituted rsv antigens, nucleic acid molecules encoding the antigens, and vaccine compositions comprising the same
Canales et al. Anaplasma marginale major surface protein 1a directs cell surface display of tick BM95 immunogenic peptides on Escherichia coli
Gebara et al. Adjuvant and immunogenic activities of the 73 kDa N-terminal α-domain of BrkA autotransporter and Cpn60/60 kDa chaperonin of Bordetella pertussis
CN118085043B (en) Mycobacterium tuberculosis multi-immunogen antigen, polynucleotide for encoding same and application thereof
WO2018085488A1 (en) Universal mammalian influenza vaccine
RU2776479C1 (en) LIVE PROBIOTIC VACCINE CONTAINING CONSERVATIVE INFLUENZA A VIRUS EPITOPES (LAH+4M2e) FOR THE PREVENTION OF INFLUENZA INFECTION
CN109232737A (en) A kind of full human monoclonal antibody for RSV attachment G protein surface antigen
US20210225457A1 (en) Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof
CN110878128A (en) Human respiratory syncytial virus mucosal vaccine and preparation method and application thereof
Van Gerven et al. Inactivated Salmonella expressing the receptor-binding domain of bacterial adhesins elicit antibodies inhibiting hemagglutination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14751295

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14768107

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/010623

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 201500770

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2014751295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201508723

Country of ref document: UA